<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027479</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO16-LO/METERMUS-IMC</org_study_id>
    <secondary_id>2016-A01323-48</secondary_id>
    <secondary_id>2016-R27</secondary_id>
    <nct_id>NCT03027479</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss</brief_title>
  <acronym>METERMUS-IMC</acronym>
  <official_title>Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inserm U1069 - Team Nutrition, Growth and Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim is to study skeletal muscle metabolism alterations métaboliques associated with
      weight loss in women with ovarian and/or endometrial cancer according to BMI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of muscle mitochondrial bioenergetics according to BMI</measure>
    <time_frame>muscle biopsy realized during surgery</time_frame>
    <description>Measurement of muscle mitochondrial bioenergetics by high resolution oxygraphy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>on muscle biopsy</measure>
    <time_frame>muscle biopsy realized during surgery</time_frame>
    <description>Quantification of lipids on electron microscope
Type of muscular fibers
Analyze of gene expression and proteins involved in 1/ Mitochondrial metabolism 2/ lipid metabolism and 3/ muscular proteolysis by RTqPCR with SyBR Green and Western Blot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on white adipose tissue</measure>
    <time_frame>adipose tissue samples taken during surgery</time_frame>
    <description>adipose tissue composition (fatty acids quantification, sterols, steroids)
RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profile and cytokines)
RTqPCR analysis, western blot and immunohistochemical expression of markers of transformation into brown adipose tissue
in specific milieu, in vitro experimentation on skeletal muscular cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on ovarian cancer tumor samples</measure>
    <time_frame>ovarian tumor biopsies realized during surgery</time_frame>
    <description>lipid composition (fatty acids quantification, sterols, steroids)
RT-qPCR quantification of molecules involved in lipid metabolism (synthesis, transport) and in inflammation (immune profil and cytokines)
culture of tumour cells to evaluate resistance to chemotherapy (platinum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>on computerized tomography</measure>
    <time_frame>1 day of abdominal CT scan imaging procedure performed at diagnosis</time_frame>
    <description>assessment of body composition (fat and muscle compartments)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Weight Loss</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample</description>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Case group selection criteria:

        Inclusion Criteria:

          -  Women aged 18 years old and more

          -  Ovarian and/or endometrial cancer

          -  weight loss related to cancer (weight loss &gt; 5% weight in one month or 10% in 6
             months)

          -  Indication to therapeutic surgery

          -  Women affiliated to social security scheme

          -  Women who can understand French and able to sign Informed consent

        Exclusion Criteria:

          -  Unbalanced Diabetes

          -  Chronic neuromuscular disorder

          -  Any severe uncontrolled medical condition

        Control group selection criteria:

        Inclusion Criteria:

          -  Women aged 18 years and more

          -  Surgery Indication for a benign endometrial and/ or ovarian disease

          -  Patient affiliated to social security scheme

          -  Women who can understand French and able to sign Informed consent

        Exclusion Criteria:

          -  Unbalanced Diabetes

          -  Chronic neuromuscular disorder

          -  Any severe uncontrolled medical condition
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lobna OULDAMER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Teaching Hospital of Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lobna OULDAMER, MD, PhD</last_name>
    <phone>+33(0)2.47.47.47.41</phone>
    <email>l.ouldamer@chu-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphane SERVAIS, PhD</last_name>
    <phone>+33(0)2.47.36.60.59</phone>
    <email>stephane.servais@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynecology Department, University Teaching Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lobna OULDAMER, MD, PhD</last_name>
      <phone>+33(0)2.47.47.47.41</phone>
      <email>l.ouldamer@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weight loss</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>energy metabolism</keyword>
  <keyword>Body mass index</keyword>
  <keyword>obesity</keyword>
  <keyword>muscle energy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

